

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

A-427

RRID:CVCL_1055

Type: Cell Line

Proper Citation

RRID:CVCL_1055

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1055

Proper Citation: RRID:CVCL_1055

Description: Cell line A-427 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:77569](#), [PMID:327080](#), [PMID:833871](#), [PMID:1855224](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3940644](#), [PMID:3945555](#), [PMID:4357758](#), [PMID:6256643](#), [PMID:6401685](#), [PMID:6500159](#), [PMID:6825208](#), [PMID:6935474](#), [PMID:7144906](#), [PMID:7459858](#), [PMID:10536175](#), [PMID:10908148](#), [PMID:11005564](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22282976](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-427

Synonyms: A427, A427N

Cross References: BTO:BTO_0003770, CLO:CLO_0001590, EFO:EFO_0002104, CLDB:cl152, CLDB:cl153, CLDB:cl5024, AddexBio:C0016004/21, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-7906, ATCC:HTB-53, BioSample:SAMN01821535, BioSample:SAMN01821613, BioSample:SAMN03471087, BioSample:SAMN10989597, cancercellines:CVCL_1055, Cell_Model_Passport:SIDM00810, ChEMBL-Cells:ChEMBL3307775, ChEMBL-Targets:ChEMBL614515, CLS:300111, Cosmic:724857, Cosmic:735606, Cosmic:801570, Cosmic:844825, Cosmic:876134, Cosmic:910851, Cosmic:917971, Cosmic:929961, Cosmic:932914, Cosmic:933581, Cosmic:961832, Cosmic:1006531, Cosmic:1146870, Cosmic:1218868, Cosmic:1239866, Cosmic:2042862, Cosmic:2125175, Cosmic:2668263, Cosmic:2668303, Cosmic-CLP:910851, DepMap:ACH-000757, DSMZ:ACC-234, DSMZCellDive:ACC-234, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:910851, GEO:GSM206444, GEO:GSM274755, GEO:GSM274756, GEO:GSM353235, GEO:GSM434323, GEO:GSM784204, GEO:GSM827284, GEO:GSM1374383, GEO:GSM1526628, GEO:GSM1526629, GEO:GSM1669585, IARC_TP53:21166, IGRhCellID:A427, IZSLER:BS TCL 120, KCLB:30053, LINCS_LDP:LCL-1600, PharmacDB:A427_45_2019, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_1055, PubChem_Cell_line:CVCL_1055, Wikidata:Q54606034

ID: CVCL_1055

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260905T184349+0000

Ratings and Alerts

No rating or validation information has been found for A-427.

Warning: Discontinued: ATCC; CRL-7906

Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells.

Cancer research, 86(8), 2024.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. *Cell reports. Medicine*, 6(7), 102235.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Ma J, et al. (2025) Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. *Molecular cancer therapeutics*, 24(8), 1171.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Biswas S, et al. (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. *Immunity*, 56(11), 2570.

Zhou L, et al. (2022) EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer. *Journal of cancer research and clinical oncology*, 148(2), 309.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. *Cancer cell*, 40(2), 136.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. *iScience*, 25(3), 103985.

Chang SC, et al. (2022) Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programmed cell death. *Cell chemical biology*, 29(11), 1601.

Kitajima S, et al. (2022) MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. *Cancer cell*, 40(10), 1128.

Zhang S, et al. (2020) The Negative Cross-Talk between SAG/RBX2/ROC2 and APC/C E3 Ligases in Regulation of Cell Cycle Progression and Drug Resistance. *Cell reports*, 32(10), 108102.

Hastings JF, et al. (2020) Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. *eLife*, 9.

Cui D, et al. (2020) FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell reports, 30(2), 497.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell chemical biology, 27(1), 105.

Zhou W, et al. (2018) UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F. Molecular cell, 70(6), 1008.